A major shift in perspective on hormone replacement therapy (HRT) for menopausal women is underway, as the U.S. Food and Drug Administration (FDA) has decided to remove the notorious "black box" warnings from many HRT medications. This decision, which affects products containing estrogen or progestogen, either alone or combined, signals a new era in how we view and approach this treatment.
The "black box" warnings, which have been a prominent feature on medication packaging, were based on outdated scientific data, according to FDA Commissioner Dr. Marty Makary and other agency officials. This outdated information has discouraged many women from seeking treatment that could be beneficial for managing troublesome menopause symptoms such as hot flashes, mood swings, and sleep difficulties, as well as reducing the risk of bone fractures.
But here's where it gets controversial: the 2002 clinical trial that led to these warnings was primarily focused on women in their 60s and 70s and used a specific hormone formulation that is not commonly prescribed today. Most women begin HRT in their 40s or 50s when menopause symptoms are at their peak.
Dr. MargEva Cole, an obstetrician-gynecologist at Duke University, highlights the psychological impact of these warnings. She notes that many women become excited about starting HRT but then, upon reading the "black box" warnings at home, become scared and decide against it.
Recent studies using current hormone formulations have not replicated the increased risk of adverse events that the 2002 trial suggested. In fact, the FDA is now recommending that women considering systemic HRT (pills or patches) start treatment before age 60 or within 10 years of menopause onset. Starting early may offer additional benefits, such as a reduced risk of cognitive decline and cardiovascular disease.
However, the agency emphasizes that the decision to use HRT is highly individualized and should be made in consultation with a doctor. It is not a one-size-fits-all solution. Dr. Samantha Dunham, director of the Center for Midlife Health and Menopause at NYU Langone Health, points out that there are alternative approaches, including cognitive therapy and non-hormonal medications.
While the broad "black box" warnings have been removed, detailed information about specific risks will still be available in package inserts. For more information, the American College of Obstetricians and Gynecologists offers resources and guidelines on menopausal hormone therapy.
So, what do you think about this shift in perspective on HRT? Do you agree with the FDA's decision to remove the "black box" warnings? Or do you think more caution is needed? We'd love to hear your thoughts in the comments below!
